| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis.
|
Cell Cycle
|
2009
|
2.03
|
|
2
|
Metformin: multi-faceted protection against cancer.
|
Oncotarget
|
2011
|
2.00
|
|
3
|
Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.
|
PLoS One
|
2009
|
1.91
|
|
4
|
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.
|
Cell Cycle
|
2009
|
1.89
|
|
5
|
Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
|
Cell Cycle
|
2010
|
1.85
|
|
6
|
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.
|
Cell Cycle
|
2010
|
1.78
|
|
7
|
The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
|
Breast Cancer Res Treat
|
2010
|
1.71
|
|
8
|
Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells.
|
Cell Cycle
|
2009
|
1.66
|
|
9
|
Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
|
Cell Cycle
|
2010
|
1.60
|
|
10
|
Metformin is synthetically lethal with glucose withdrawal in cancer cells.
|
Cell Cycle
|
2012
|
1.39
|
|
11
|
mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging.
|
Cell Cycle
|
2011
|
1.32
|
|
12
|
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.
|
Aging (Albany NY)
|
2012
|
1.31
|
|
13
|
AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor.
|
Cell Cycle
|
2009
|
1.23
|
|
14
|
The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.
|
Cell Cycle
|
2013
|
1.20
|
|
15
|
Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype.
|
Cell Cycle
|
2011
|
1.19
|
|
16
|
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
|
Oncotarget
|
2012
|
1.14
|
|
17
|
Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells.
|
Cell Cycle
|
2012
|
1.14
|
|
18
|
The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer.
|
Sci Rep
|
2013
|
1.14
|
|
19
|
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
|
Sci Rep
|
2012
|
1.11
|
|
20
|
Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
|
Cell Cycle
|
2011
|
1.09
|
|
21
|
Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.
|
Cell Cycle
|
2013
|
1.08
|
|
22
|
Gerosuppressant metformin: less is more.
|
Aging (Albany NY)
|
2011
|
1.08
|
|
23
|
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.
|
Sci Rep
|
2013
|
1.07
|
|
24
|
Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKalphaThr172) in human cancer cells.
|
Cell Cycle
|
2009
|
1.06
|
|
25
|
The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells.
|
Cell Cycle
|
2012
|
1.04
|
|
26
|
If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.
|
J Clin Oncol
|
2009
|
1.01
|
|
27
|
Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
|
Int J Oncol
|
2009
|
1.01
|
|
28
|
Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer.
|
Aging (Albany NY)
|
2011
|
1.01
|
|
29
|
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.
|
Drug Resist Updat
|
2011
|
1.01
|
|
30
|
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
|
J Cell Physiol
|
2011
|
1.00
|
|
31
|
Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response.
|
Cell Cycle
|
2011
|
1.00
|
|
32
|
Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents.
|
Cell Cycle
|
2013
|
1.00
|
|
33
|
mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).
|
Clin Transl Oncol
|
2009
|
0.96
|
|
34
|
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
|
Cell Cycle
|
2012
|
0.95
|
|
35
|
Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205.
|
Cell Cycle
|
2012
|
0.92
|
|
36
|
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.
|
Sci Rep
|
2013
|
0.91
|
|
37
|
The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.
|
Oncol Rep
|
2011
|
0.90
|
|
38
|
tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO).
|
BMC Cancer
|
2008
|
0.88
|
|
39
|
Characterization and quantification of phenolic compounds of extra-virgin olive oils with anticancer properties by a rapid and resolutive LC-ESI-TOF MS method.
|
J Pharm Biomed Anal
|
2009
|
0.87
|
|
40
|
Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs).
|
Cell Cycle
|
2011
|
0.86
|
|
41
|
Prediction of extra virgin olive oil varieties through their phenolic profile. Potential cytotoxic activity against human breast cancer cells.
|
J Agric Food Chem
|
2010
|
0.85
|
|
42
|
Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
|
Food Chem Toxicol
|
2013
|
0.85
|
|
43
|
Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals.
|
Rejuvenation Res
|
2012
|
0.84
|
|
44
|
Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays.
|
Int J Mol Med
|
2008
|
0.84
|
|
45
|
Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies.
|
Genes Chromosomes Cancer
|
2011
|
0.84
|
|
46
|
The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells.
|
Biochem Biophys Res Commun
|
2009
|
0.83
|
|
47
|
Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
|
Cell Cycle
|
2013
|
0.83
|
|
48
|
Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection.
|
BMC Gastroenterol
|
2010
|
0.82
|
|
49
|
Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis.
|
Cell Cycle
|
2012
|
0.81
|
|
50
|
Polo-like kinase 1 directs the AMPK-mediated activation of myosin regulatory light chain at the cytokinetic cleavage furrow independently of energy balance.
|
Cell Cycle
|
2012
|
0.81
|
|
51
|
Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contrast mitosis marker in breast cancer core biopsies.
|
Int J Oncol
|
2010
|
0.81
|
|
52
|
Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2.
|
Int J Oncol
|
2009
|
0.81
|
|
53
|
Serine79-phosphorylated acetyl-CoA carboxylase, a downstream target of AMPK, localizes to the mitotic spindle poles and the cytokinesis furrow.
|
Cell Cycle
|
2013
|
0.80
|
|
54
|
Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis.
|
Clin Chem Lab Med
|
2009
|
0.79
|
|
55
|
Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics.
|
Oncotarget
|
2014
|
0.76
|
|
56
|
Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib.
|
Breast Cancer Res
|
2011
|
0.75
|
|
57
|
Uptake and metabolism of olive oil polyphenols in human breast cancer cells using nano-liquid chromatography coupled to electrospray ionization-time of flight-mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2012
|
0.75
|
|
58
|
A 2-D-HPLC-CE platform coupled to ESI-TOF-MS to characterize the phenolic fraction in olive oil.
|
Electrophoresis
|
2009
|
0.75
|
|
59
|
Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast.
|
Breast Cancer Res Treat
|
2010
|
0.75
|
|
60
|
Antibody microarray-based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma.
|
J Surg Oncol
|
2011
|
0.75
|